AU2010303364B2 - Combination - Google Patents

Combination Download PDF

Info

Publication number
AU2010303364B2
AU2010303364B2 AU2010303364A AU2010303364A AU2010303364B2 AU 2010303364 B2 AU2010303364 B2 AU 2010303364B2 AU 2010303364 A AU2010303364 A AU 2010303364A AU 2010303364 A AU2010303364 A AU 2010303364A AU 2010303364 B2 AU2010303364 B2 AU 2010303364B2
Authority
AU
Australia
Prior art keywords
compound
administered
suitably
days
consecutive days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010303364A
Other languages
English (en)
Other versions
AU2010303364A1 (en
Inventor
Melissa Dumble
Tona Gilmer
Rakesh Kumar
Sylvie Laquerre
Peter F. Lebowitz
Shannon Renae Morris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2010303364A1 publication Critical patent/AU2010303364A1/en
Application granted granted Critical
Publication of AU2010303364B2 publication Critical patent/AU2010303364B2/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG Request for Assignment Assignors: GLAXOSMITHKLINE LLC
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2010303364A 2009-10-08 2010-10-08 Combination Ceased AU2010303364B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24980809P 2009-10-08 2009-10-08
US61/249,808 2009-10-08
PCT/US2010/051909 WO2011044415A1 (en) 2009-10-08 2010-10-08 Combination

Publications (2)

Publication Number Publication Date
AU2010303364A1 AU2010303364A1 (en) 2012-04-26
AU2010303364B2 true AU2010303364B2 (en) 2013-09-19

Family

ID=43857163

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010303364A Ceased AU2010303364B2 (en) 2009-10-08 2010-10-08 Combination

Country Status (14)

Country Link
US (1) US8796298B2 (enExample)
EP (1) EP2485594B1 (enExample)
JP (1) JP5881607B2 (enExample)
KR (1) KR101696003B1 (enExample)
CN (1) CN102647908B (enExample)
AU (1) AU2010303364B2 (enExample)
BR (1) BR112012008274A2 (enExample)
CA (1) CA2777087C (enExample)
EA (1) EA023018B1 (enExample)
ES (1) ES2530436T3 (enExample)
IL (1) IL219000A (enExample)
MX (1) MX2012004140A (enExample)
WO (1) WO2011044415A1 (enExample)
ZA (1) ZA201202495B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG191724A1 (en) 2011-01-11 2013-08-30 Glaxosmithkline Llc Combination
CN104540822B (zh) * 2013-07-08 2016-08-31 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的晶型及其制备方法
WO2016190897A1 (en) * 2015-05-27 2016-12-01 Quest Diagnostics Investments Incorporated Compositions and methods for screening solid tumors
EP3849536A4 (en) * 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750217B2 (en) * 1999-01-13 2004-06-15 Warner-Lambert Company Benzenesulfonamide derivatives and their use as MEK inhibitors
US20050113423A1 (en) * 2003-03-12 2005-05-26 Vangoor Frederick F. Modulators of ATP-binding cassette transporters
WO2007084391A2 (en) * 2006-01-18 2007-07-26 Amgen Inc. Thiazole compounds as protein kinase b ( pkb) inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750217B2 (en) * 1999-01-13 2004-06-15 Warner-Lambert Company Benzenesulfonamide derivatives and their use as MEK inhibitors
US20050113423A1 (en) * 2003-03-12 2005-05-26 Vangoor Frederick F. Modulators of ATP-binding cassette transporters
WO2007084391A2 (en) * 2006-01-18 2007-07-26 Amgen Inc. Thiazole compounds as protein kinase b ( pkb) inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Tsai.J. et al., PNAS, 2008, Vol 105(8), Pages 3041-3046 *

Also Published As

Publication number Publication date
KR101696003B1 (ko) 2017-01-13
CN102647908B (zh) 2014-02-19
EA023018B1 (ru) 2016-04-29
EP2485594B1 (en) 2015-01-07
JP5881607B2 (ja) 2016-03-09
ES2530436T3 (es) 2015-03-02
CA2777087C (en) 2017-10-31
KR20120093931A (ko) 2012-08-23
ZA201202495B (en) 2013-01-30
JP2013507383A (ja) 2013-03-04
CA2777087A1 (en) 2011-04-14
EP2485594A1 (en) 2012-08-15
IL219000A0 (en) 2012-06-28
MX2012004140A (es) 2012-09-07
US8796298B2 (en) 2014-08-05
AU2010303364A1 (en) 2012-04-26
WO2011044415A1 (en) 2011-04-14
BR112012008274A2 (pt) 2015-09-22
EA201270527A1 (ru) 2012-12-28
EP2485594A4 (en) 2013-02-13
IL219000A (en) 2015-02-26
US20120202835A1 (en) 2012-08-09
CN102647908A (zh) 2012-08-22

Similar Documents

Publication Publication Date Title
US9402846B2 (en) Combination of inhibitor of B-Raf and inhibitor of AKT in the treatment of cancer
AU2010303364B2 (en) Combination
US20160213672A1 (en) Combination
US20150094283A1 (en) Combination
US20150272950A1 (en) Combination
AU2013334943A1 (en) Combination

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NOVARTIS AG

Free format text: FORMER OWNER(S): GLAXOSMITHKLINE LLC

MK14 Patent ceased section 143(a) (annual fees not paid) or expired